Cellectar Biosciences posts positive Phase 2b CLOVER WaM data supporting FDA accelerated approval path for iopofosine I 131 in Waldenström macroglobulinemia
Tuesday, May 5, 2026
Edgewise positive Phase 2 interim data for EDG-7500 in hypertrophic cardiomyopathy
Edgewise announced completion of Parts B and C of the trial along with favorable interim results from the ongoing Part D open-label extension in patients with obstructive and non-obstructive HCM. EDG-7500 showed a strong safety profile with no clinically meaningful LVEF reductions below 50%, no treatment-related atrial fibrillation events across extensive monitoring, and signals of clinical activity on key markers such as NT-proBNP, KCCQ, NYHA class, and LVOT gradient. This update reinforces the drug’s differentiated profile versus existing cardiac myosin inhibitors, de-risking the cardiac sarcomere modulator program ahead of additional efficacy readouts and potential Phase 3 progression. The news triggered heavy premarket volume and buying interest, lifting shares approximately 21% in early trading on May 5, 2026, from the prior close near $31.45.
Subscribe to:
Posts (Atom)